These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 9932994)
21. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension. Frampton JE Drugs Aging; 2006; 23(9):753-61. PubMed ID: 17020399 [TBL] [Abstract][Full Text] [Related]
22. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466 [TBL] [Abstract][Full Text] [Related]
23. Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide. Hommer A; Kapik B; Shams N; Br J Ophthalmol; 2003 May; 87(5):592-8. PubMed ID: 12714402 [TBL] [Abstract][Full Text] [Related]
24. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. March WF; Ochsner KI Am J Ophthalmol; 2000 Feb; 129(2):136-43. PubMed ID: 10682964 [TBL] [Abstract][Full Text] [Related]
25. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy. Motolko MA Curr Med Res Opin; 2008 Sep; 24(9):2663-7. PubMed ID: 18691444 [TBL] [Abstract][Full Text] [Related]
26. A short term study of the additive effect of timolol and brimonidine on intraocular pressure. Arici MK; Sayici M; Toker M; Erdoğan H; Topalkara A Eye (Lond); 2002 Jan; 16(1):39-43. PubMed ID: 11913886 [TBL] [Abstract][Full Text] [Related]
27. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Krupin T; Liebmann JM; Greenfield DS; Ritch R; Gardiner S; Am J Ophthalmol; 2011 Apr; 151(4):671-81. PubMed ID: 21257146 [TBL] [Abstract][Full Text] [Related]
28. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Boyle JE; Ghosh K; Gieser DK; Adamsons IA Ophthalmology; 1999 Dec; 106(12 Suppl):10-6. PubMed ID: 10598692 [TBL] [Abstract][Full Text] [Related]
29. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure. Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465 [TBL] [Abstract][Full Text] [Related]
30. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Adkins JC; Balfour JA Drugs Aging; 1998 Mar; 12(3):225-41. PubMed ID: 9534022 [TBL] [Abstract][Full Text] [Related]
31. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study. Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918 [TBL] [Abstract][Full Text] [Related]
32. Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertension. Sharpe ED; Henry CJ; Mundorf TK; Day DG; Stewart JA; Jenkins JN; Stewart WC Eye (Lond); 2005 Jan; 19(1):35-40. PubMed ID: 15094733 [TBL] [Abstract][Full Text] [Related]
33. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. Katz LJ J Glaucoma; 2002 Apr; 11(2):119-26. PubMed ID: 11912359 [TBL] [Abstract][Full Text] [Related]
34. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma. Centofanti M; Manni G; Gregori D; Cocco F; Lorenzano D; Bucci MG Graefes Arch Clin Exp Ophthalmol; 2000 Apr; 238(4):302-5. PubMed ID: 10853928 [TBL] [Abstract][Full Text] [Related]
35. Treatment of patients with primary open-angle glaucoma with a fixed combination of brimonidine 0.2%/timolol 0.5%: multicenter, open-label, observational study in Germany. Thelen U; Buchholz P; Kimmich F Curr Med Res Opin; 2009 Apr; 25(4):1003-9. PubMed ID: 19275517 [TBL] [Abstract][Full Text] [Related]
36. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension. Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922 [TBL] [Abstract][Full Text] [Related]
37. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Goñi FJ; Eur J Ophthalmol; 2005; 15(5):581-90. PubMed ID: 16167288 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Stewart WC; Stewart JA; Day D; Sharpe ED Acta Ophthalmol Scand; 2003 Jun; 81(3):242-6. PubMed ID: 12780402 [TBL] [Abstract][Full Text] [Related]
39. A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension. Hommer A; Sperl P; Resch H; Popa-Cherecheanu A; Qiao C; Schmetterer L; Garhöfer G J Ocul Pharmacol Ther; 2012 Dec; 28(6):569-75. PubMed ID: 22775229 [TBL] [Abstract][Full Text] [Related]
40. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension. Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]